A Study to Assess the Dose, Adverse Events, and Change in Disease Activity of Livmoniplimab as an Intravenous (IV) Solution in Combination With Budigalimab as an IV Solution in Adult Participants With Hepatocellular Carcinoma (HCC)

Conditions: Hepatocellular Carcinoma Interventions: Drug: Livmoniplimab; Drug: Budigalimab; Drug: Durvalumab; Drug: Atezolizumab; Drug: Bevacizumab; Drug: Tremelimumab Sponsors: AbbVie Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials